Tiziana Life Sciences Announces Death of Director
Tiziana Life Sciences (Nasdaq: TLSA) announced the passing of Dr. Thomas Adams on January 9, 2022. He had served on the company's Board of Directors since February 2021. CEO Kunwar Shailubhai expressed deep sadness over Dr. Adams' loss, highlighting his value and inspiration to the team. Tiziana is focused on developing transformative therapies through innovative drug delivery methods, such as intranasal and oral routes, which aim to enhance safety and efficacy. The company’s lead candidates include intranasal foralumab and milciclib, showing promising safety profiles in clinical studies.
- Tiziana's innovative drug delivery technologies are in development, potentially improving efficacy and safety.
- Lead candidates, intranasal foralumab and milciclib, demonstrated favorable safety profiles and clinical responses.
- None.
NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that Dr. Thomas Adams passed away on January 9, 2022. He served as a member of Tiziana Life Science’s Board of Directors since February 2021.
Dr. Kunwar Shailubhai, the Company's CEO, commented, "It is with great sadness that we announce the passing of Dr. Tom Adams. He was a highly valued Director of the Company and was an inspiration to all of us. Although he joined the Board a year ago, Dr. Adams had been involved with Tiziana over a number of years. He will be missed not only as a business colleague, but also as a friend. We extend our deepest sympathies to the entire Adams family."
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
| For further enquiries: United Kingdom: Tiziana Life Sciences Ltd. Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379 | |
| United States: Irina Koffler LifeSci Advisors, LLC 646.970.4681 ikoffler@lifesciadvisors.com |
FAQ
What happened to Dr. Thomas Adams from Tiziana Life Sciences?
What is Tiziana Life Sciences known for?
What are Tiziana's lead drug candidates?
When did Dr. Adams join Tiziana's Board of Directors?
